Definitions

from Wiktionary, Creative Commons Attribution/Share-Alike License

  • n. A human monoclonal antibody used as an immunosuppressive drug.

Etymologies

from Wiktionary, Creative Commons Attribution/Share-Alike License

-mu- + -mab

Examples

  • Also known as golimumab, Simponi is a follow-up drug to Remicade, which treats rheumatoid arthritis and gastrointestinal conditions.

    U.K.' Regulator Backs Merck's Rheumatoid Arthritis Drug

  • One potential stumbling block is that Schering-Plough shares the rights to blockbuster arthritis treatment Remicade and a new arthritis therapy in late-stage development called golimumab, with J&J.

    Merck to Buy Rival for $41 Billion

  • The treatment, called golimumab, is an anti-TNF, or tumor necrosis factor, which reduces inflammation and combats some immune-system diseases.

    Arthritis Treatment Shown Effective

  • The deal is being structured as a reverse merger in an attempt to avoid triggering change-of-control provisions in Schering-Plough's partnership with Johnson & Johnson for two biologic drugs for rheumatoid arthritis, the blockbuster Remicade and golimumab, which is in late-stage testing.

    undefined

  • We're glad that extra information from the manufacturer has meant that our appraisal committee now feels confident in recommending golimumab as a fourth-treatment option.

    U.K.' Regulator Backs Merck's Rheumatoid Arthritis Drug

  • NICE said its backing is dependent on a patient-access scheme agreed between the manufacturer and the U.K.'s Department of Health, whereby Merck provides both of the available doses of golimumab of 50 milligrams and 100 mg to the NHS at the cost of the 50 mg dose.

    U.K.' Regulator Backs Merck's Rheumatoid Arthritis Drug

  • Merck's submission set the cost of golimumab at £775 $1,242 for a 50 mg pre-filled injection pen, with an estimated annual cost of £9,295.

    U.K.' Regulator Backs Merck's Rheumatoid Arthritis Drug

  • -- Immunology: Schering-Plough brings distribution rights outside the United States to REMICADE (infliximab), its well-established biologic product for inflammatory/immunological diseases, and SIMPONI (golimumab), which was filed in Europe in March 2008, as well as a number of other promising products in development.

    Merck, Schering-Plough Statement

  • Also, Merck executives played down the importance of holding onto Remicade and golimumab.

    Deal Complicates Rights to Big Drug

  • Merck executives say the acquisition of Schering-Plough won't trigger the change-of-control provision in the J&J/Schering marketing agreement for Remicade and golimumab.

    Deal Complicates Rights to Big Drug

Comments

Log in or sign up to get involved in the conversation. It's quick and easy.